Endovascular  ||| S:0 E:13 ||| JJ
treatment  ||| S:13 E:23 ||| NN
of  ||| S:23 E:26 ||| IN
intracranial  ||| S:26 E:39 ||| NNS
stenosis  ||| S:39 E:48 ||| VBP
The  ||| S:48 E:52 ||| DT
Gateway  ||| S:52 E:60 ||| JJ
balloon-Wingspan  ||| S:60 E:77 ||| JJ
stent  ||| S:77 E:83 ||| JJ
system  ||| S:83 E:90 ||| NN
is  ||| S:90 E:93 ||| VBZ
the  ||| S:93 E:97 ||| DT
first ||| S:97 E:102 ||| JJ
,  ||| S:102 E:104 ||| ,
and  ||| S:104 E:108 ||| CC
currently  ||| S:108 E:118 ||| RB
the  ||| S:118 E:122 ||| DT
only  ||| S:122 E:127 ||| JJ
on-label  ||| S:127 E:136 ||| JJ
device  ||| S:136 E:143 ||| NN
for  ||| S:143 E:147 ||| IN
the  ||| S:147 E:151 ||| DT
treatment  ||| S:151 E:161 ||| NN
of  ||| S:161 E:164 ||| IN
symptomatic  ||| S:164 E:176 ||| JJ
intracranial  ||| S:176 E:189 ||| JJ
stenosis  ||| S:189 E:198 ||| NN
in  ||| S:198 E:201 ||| IN
the  ||| S:201 E:205 ||| DT
United  ||| S:205 E:212 ||| NNP
States ||| S:212 E:218 ||| NNPS
.  ||| S:218 E:220 ||| .
In  ||| S:220 E:223 ||| IN
initial  ||| S:223 E:231 ||| JJ
single-arm  ||| S:231 E:242 ||| JJ
studies ||| S:242 E:249 ||| NNS
,  ||| S:249 E:251 ||| ,
investigators  ||| S:251 E:265 ||| NNS
have  ||| S:265 E:270 ||| VBP
indicated  ||| S:270 E:280 ||| VBN
that  ||| S:280 E:285 ||| IN
this  ||| S:285 E:290 ||| DT
system  ||| S:290 E:297 ||| NN
can  ||| S:297 E:301 ||| MD
be  ||| S:301 E:304 ||| VB
used  ||| S:304 E:309 ||| VBN
for  ||| S:309 E:313 ||| IN
the  ||| S:313 E:317 ||| DT
treatment  ||| S:317 E:327 ||| NN
of  ||| S:327 E:330 ||| IN
symptomatic  ||| S:330 E:342 ||| JJ
intracranial  ||| S:342 E:355 ||| JJ
atherosclerotic  ||| S:355 E:371 ||| JJ
disease  ||| S:371 E:379 ||| NN
with  ||| S:379 E:384 ||| IN
high  ||| S:384 E:389 ||| JJ
levels  ||| S:389 E:396 ||| NNS
of  ||| S:396 E:399 ||| IN
technical  ||| S:399 E:409 ||| JJ
success  ||| S:409 E:417 ||| NN
and  ||| S:417 E:421 ||| CC
acceptable  ||| S:421 E:432 ||| JJ
periprocedural  ||| S:432 E:447 ||| JJ
complication  ||| S:447 E:460 ||| NN
rates ||| S:460 E:465 ||| NNS
,  ||| S:465 E:467 ||| ,
which  ||| S:467 E:473 ||| WDT
are  ||| S:473 E:477 ||| VBP
comparable  ||| S:477 E:488 ||| JJ
with ||| S:488 E:492 ||| IN
,  ||| S:492 E:494 ||| ,
or  ||| S:494 E:497 ||| CC
better  ||| S:497 E:504 ||| JJR
than ||| S:504 E:508 ||| IN
,  ||| S:508 E:510 ||| ,
those  ||| S:510 E:516 ||| DT
reported  ||| S:516 E:525 ||| VBN
for  ||| S:525 E:529 ||| IN
other  ||| S:529 E:535 ||| JJ
endovascular  ||| S:535 E:548 ||| JJ
techniques ||| S:548 E:558 ||| NNS
.  ||| S:558 E:560 ||| .
Intermediate-  ||| S:560 E:574 ||| NNP
and  ||| S:574 E:578 ||| CC
long-term  ||| S:578 E:588 ||| JJ
follow-up  ||| S:588 E:598 ||| JJ
data  ||| S:598 E:603 ||| NNS
for  ||| S:603 E:607 ||| IN
patients  ||| S:607 E:616 ||| NNS
treated  ||| S:616 E:624 ||| VBN
with  ||| S:624 E:629 ||| IN
the  ||| S:629 E:633 ||| DT
Wingspan  ||| S:633 E:642 ||| JJ
device  ||| S:642 E:649 ||| NN
remain  ||| S:649 E:656 ||| VBP
sparse ||| S:656 E:662 ||| VBN
.  ||| S:662 E:664 ||| .
We  ||| S:664 E:667 ||| PRP
critically  ||| S:667 E:678 ||| RB
review  ||| S:678 E:685 ||| VB
the  ||| S:685 E:689 ||| DT
existing  ||| S:689 E:698 ||| JJ
data ||| S:698 E:702 ||| NNS
,  ||| S:702 E:704 ||| ,
which  ||| S:704 E:710 ||| WDT
characterize  ||| S:710 E:723 ||| VBP
the  ||| S:723 E:727 ||| DT
risk  ||| S:727 E:732 ||| NN
profile  ||| S:732 E:740 ||| NN
and  ||| S:740 E:744 ||| CC
efficacy  ||| S:744 E:753 ||| NN
of  ||| S:753 E:756 ||| IN
endovascular  ||| S:756 E:769 ||| JJ
interventions  ||| S:769 E:783 ||| NNS
for  ||| S:783 E:787 ||| IN
intracranial  ||| S:787 E:800 ||| JJ
atherosclerotic  ||| S:800 E:816 ||| JJ
disease ||| S:816 E:823 ||| NN
,  ||| S:823 E:825 ||| ,
as  ||| S:825 E:828 ||| RB
well  ||| S:828 E:833 ||| RB
as  ||| S:833 E:836 ||| IN
the  ||| S:836 E:840 ||| DT
available  ||| S:840 E:850 ||| JJ
clinical  ||| S:850 E:859 ||| JJ
evidence  ||| S:859 E:868 ||| NN
that  ||| S:868 E:873 ||| WDT
could  ||| S:873 E:879 ||| MD
be  ||| S:879 E:882 ||| VB
used  ||| S:882 E:887 ||| VBN
to  ||| S:887 E:890 ||| TO
select  ||| S:890 E:897 ||| VB
appropriate  ||| S:897 E:909 ||| JJ
patients  ||| S:909 E:918 ||| NNS
for  ||| S:918 E:922 ||| IN
treatment ||| S:922 E:931 ||| NN
.  ||| S:931 E:933 ||| .
